Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Rectal Neoplasms 3Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oesophagogastric Cancer 1Neoplasms 1Inflammatory Breast Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 6liposomal doxorubicin 4Carboplatin 4Topotecan 3Drug Therapy 3Gemcitabine 2Doxorubicin 2Bevacizumab 21-dodecylpyridoxal 2trametinib 1saracatinib 1pertuzumab 1pembrolizumab 1pegfilgrastim 1olaparib 1masitinib 1dabrafenib 1cyclopropapyrroloindole 1cobimetinib 1cediranib 1atezolizumab 1aflibercept 1abagovomab 1Vemurafenib 1Trastuzumab 1Taxes 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1NP-G2-044 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Ovarian Neoplasms × Neoadjuvant Therapy × Clear all
NCT00075712 2013-08-12

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
150 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡